Objective
New drugs that predominantly target amino acids in the HIV-1 RT pocket that cannot mutate without seriously compromising RT function will be developed. Subunitdimerisation of HIV-1 RT p66/p51 will be explored as a new tool for drug development. Also a recently discovered new micro target on RT will be investigated for development of drugs that lack cross-resistance to Notes and Norris . We will develop modalities to control endogenous dent pool ratios to attenuate the resistance spectrum of Nets and Knurls . Finally, we will develop a small animal model based on cats that are infectable by an FIV clone in which the RT has been made sensitive to the HIV-1-specific Norris, to fill the existing preclinical gap between HIV resistance research in cell culture and in the clinical setting.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistance
- natural scienceschemical sciencesorganic chemistryamines
You need to log in or register to use this function
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
3000 LOUVAIN / LEUVEN
Belgium